リンコマイシンとエリトロマイシンとの間の薬物対抗性

L J GRIFFITH, W E OSTRANDER, C G MULLINS

Science (New York, N.Y.)

|February 12, 1965

まとめ

リンコミシンとエリトロミシンは,耐性菌株のスタフィロコッカス菌に抗作用を示す. エリトロミシンは細菌の代謝を変化させ,リンコミシンを増加させます.

科学分野:

微生物学微生物学とは
薬理学薬理学とは
抗生物質耐性菌は,抗生物質耐性菌として存在します.

背景:

Staphylococcus菌株は,エリトロミシンなどの抗生物質に対する耐性を発達させることがあります.
薬物相互作用を理解することは,効果的な抗微生物療法にとって極めて重要です.

研究の目的:

リンコミシンとエリトロミシンとの相互作用を,スタフィロコッカス菌株で調査する.
この2つの抗生物質の間の対抗性のメカニズムを決定する.

主な方法:

エリトロマイシンに耐性があるがリンコマイシンに敏感なスタフィロコッカス菌株を用いたアガー拡散測定法.
リンコマイシンの最小抑制濃度 (MIC) を決定する.

主要な成果:

リンコマイシンとエリトロマイシンとの間に敵対的な効果が観察されました.
エリトロミシンは,リンコマイシンの最小阻害濃度を有意に増加させた.
抗作用は,エリトロマイシンによって誘発された細菌の代謝の変化から生じ,直接的な薬物相互作用から生じていないようです.

結論:

エリトロミシンは,エリトロミシンに耐性のあるスタフィロコクスのリンコミシン活性に対抗します.
変化した細菌の代謝は,この観察された薬物対抗性の背後にある可能性が高いメカニズムです.
これらの発見は,耐性スタフィロコクスの菌株によって引き起こされる感染症の治療に潜在的臨床的影響を及ぼします.

キーワード:

抗生物質抗生物質は,抗生物質に作用する.薬剤耐性,微生物耐性について ERYTHROMYCININ エリトロミックシン実験実験室での研究リンコミックシン (LINCOMYCIN) とは薬理学 (Pharmacology) とは,薬理学 (Pharmacology) とは,薬理学 (Pharmacology) とは,薬理学 (Pharmacology) とは STAPHYLOCOCCUSUSとは,スタフィロコックスのことです.

さらに関連する動画

09:09

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

関連する概念動画

01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...

01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...

01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...

01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...

01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

関連する実験動画